

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

INTEGRATED BIOPHARMA INC
Form SC 13D
December 20, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D

(Amendment No. 2)

UNDER THE SECURITIES EXCHANGE ACT OF 1934

INTEGRATED BIOPHARMA, INC.
(Name of Issuer)

COMMON STOCK, PAR VALUE \$.002
(Title of Class of Securities)

45811V105
(CUSIP Number)

E. GERALD KAY
225 LONG AVENUE
HILLSIDE, NEW JERSEY 07205
(888) 319-6962

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

Copy to:

Andrew Abramowitz, Esq.
Greenberg Traurig, LLP
200 Park Avenue
New York, New York 10166

DECEMBER 20, 2006

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

(Page 1 of 15)

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

14 TYPE OF REPORTING PERSON*

OO

CUSIP NO. 45811V105

SCHEDULE 13D
Page 4 of 15 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

RIVA KAY SHEPPARD

2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP*

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS*

PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

UNITED STATES

7 SOLE VOTING POWER

1,050,109

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

8 SHARED VOTING POWER

169,358

9 SOLE DISPOSITIVE POWER

1,050,109

10 SHARED DISPOSITIVE POWER

169,358

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,219,467

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.6%

14 TYPE OF REPORTING PERSON*

IN

CUSIP NO. 45811V105

SCHEDULE 13D
Page 5 of 15 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

CHRISTINA KAY

2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP*

(a)

(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS*

PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

UNITED STATES

7 SOLE VOTING POWER

1,050,109

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

8 SHARED VOTING POWER

169,358

9 SOLE DISPOSITIVE POWER

1,050,109

10 SHARED DISPOSITIVE POWER

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

169,358

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,219,467

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.6%

14 TYPE OF REPORTING PERSON*

IN

CUSIP NO. 45811V105

SCHEDULE 13D
Page 6 of 15 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

ROBERT B. KAY

2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP*

(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS*

PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

UNITED STATES

7 SOLE VOTING POWER

400,000

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON

8 SHARED VOTING POWER

819,629

9 SOLE DISPOSITIVE POWER

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

WITH

400,000

10 SHARED DISPOSITIVE POWER

819,629

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,219,629

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.7%

14 TYPE OF REPORTING PERSON*

IN

CUSIP NO. 45811V105

SCHEDULE 13D
Page 7 of 15 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

EVJ, LLC

2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP*

(a) [x]
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

DELAWARE

7 SOLE VOTING POWER

0

NUMBER OF

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 8 SHARED VOTING POWER 819,629 ----- 9 SOLE DISPOSITIVE POWER 0 ----- 10 SHARED DISPOSITIVE POWER 819,629 ----- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 819,629 ----- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [] ----- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.1% ----- 14 TYPE OF REPORTING PERSON* OO -----

CUSIP NO. 45811V105

SCHEDULE 13D
Page 8 of 15 Pages

1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) CARL DESANTIS ----- 2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP* (a) [x] (b) [] ----- 3 SEC USE ONLY ----- 4 SOURCE OF FUNDS* PF ----- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [] ----- 6 CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

7 SOLE VOTING POWER
1,540,788

NUMBER OF
SHARES 8 SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH
REPORTING PERSON 819,629
WITH 9 SOLE DISPOSITIVE POWER
1,540,788

10 SHARED DISPOSITIVE POWER
819,629

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,360,417

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
17.1%

14 TYPE OF REPORTING PERSON*
IN

CUSIP NO. 45811V105

SCHEDULE 13D
Page 9 of 15 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
CDS GROUP HOLDINGS, LLC

2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP*
(a) [x]
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*
WC

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

[FLORIDA]

7 SOLE VOTING POWER

0

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

8 SHARED VOTING POWER

819,629

9 SOLE DISPOSITIVE POWER

0

10 SHARED DISPOSITIVE POWER

819,629

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

819,629

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

6.1%

14 TYPE OF REPORTING PERSON*

OO

CUSIP NO. 45811V105

SCHEDULE 13D
Page 10 of 15 Pages

1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

SEYMOUR FLUG

2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP*

(a) [x]

(b) []

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

3 SEC USE ONLY

4 SOURCE OF FUNDS*

PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

UNITED STATES

7 SOLE VOTING POWER

1,245,033

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

8 SHARED VOTING POWER

0

9 SOLE DISPOSITIVE POWER

1,245,033

10 SHARED DISPOSITIVE POWER

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,245,033

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.6%

14 TYPE OF REPORTING PERSON*

IN

CUSIP NO. 45811V105

SCHEDULE 13D
Page 11 of 15 Pages

ITEM 1. SECURITY AND ISSUER.

This Amendment No. 2 (the "Amendment") relates to shares (the "Shares") of the Common Stock, par value \$0.002 per share (the "Common Stock") of Integrated BioPharma, Inc., a Delaware corporation (the "Issuer") acquired by

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

the Reporting Persons. This Amendment amends in its entirety the Statement of Beneficial Ownership on Schedule 13D, originally filed with the Securities and Exchange Commission (the "Commission") by Trade Investment Services, L.L.C., EVJ, LLC, EGK, LLC, CDS International Holdings, Inc., Robert B. Kay, E. Gerald Kay and Carl DeSantis on March 28, 2003 and amended by Amendment No. 1, filed on July 22, 2003. The principal executive offices of the Issuer are located at 225 Long Avenue Hillside, New Jersey 07205.

ITEM 2. IDENTITY AND BACKGROUND.

The names of the Reporting Persons are E. Gerald Kay, EGK, LLC, Riva Kay Sheppard, Christina Kay, Robert B. Kay, EVJ, LLC, Carl DeSantis, CDS Group Holdings, LLC and Seymour Flug (collectively, the "Group"). EGK, LLC and EVJ, LLC are organized under the laws of the State of Delaware and CDS Group Holdings, LLC is organized under the laws of the State of Florida. The rest of the members of the Group are citizens of the United States of America.

The business address for the Group, except as set forth below, is c/o Integrated BioPharma, Inc., 225 Long Avenue Hillside, New Jersey 07205.

E. Gerald Kay Chief Executive Officer of the Issuer

EGK, LLC

Riva Kay Sheppard, Vice President of the Issuer

Christina Kay, Vice President of the Issuer

Robert B. Kay, Chairman of the Board of Paxis Pharmaceuticals

EVJ, LLC

Carl DeSantis, President of CDS Holdings, Inc., 95 NE 4th Avenue
Delray Beach, Florida 33483

CDS Group Holdings, LLC, 95 NE 4th Avenue Delray Beach, Florida 33483

Seymour Flug, Senior Advisor to the Issuer

During the last five years, no members of the Group have been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

EGK, LLC, EVJ, LLC and CDS Group Holdings, LLC, used their working capital, and the other members of the Group used personal funds to purchase the Shares for investment purposes.

ITEM 4. PURPOSE OF TRANSACTION.

Each member of the Group purchased the Shares for investment purposes and not with the view to sell in connection with any distribution thereof. Except in the ordinary course of business, the Group

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

CUSIP NO. 45811V105

SCHEDULE 13D
Page 12 of 15 Pages

has no present intention or plans or proposals which relate to or could result in any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Notwithstanding anything to the contrary contained herein, each member of the Group reserves the right, depending on all relevant factors, to change its intention with respect to any and all of the matters referred to above.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

(a) The members of the Group individually, and as a whole, may be deemed to have beneficial ownership of 12,972,569 shares of Common Stock of the Issuer, representing approximately 73.2% of the Issuer's outstanding shares of Common Stock (the percentage of shares owned being based upon 13,544,951 shares outstanding on November 17, 2006).

(b) E. Gerald Kay holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 4,550,211 shares of Common Stock. E. Gerald Kay may additionally be deemed to share beneficial ownership as well as voting and dispositive power with Riva Kay Sheppard with respect to 169,358 shares of Common Stock and with Christina Kay with respect to 169,358 shares of Common Stock. E. Gerald Kay is the manager of EGK LLC, and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) of the 819,629 shares of Common Stock held by EGK LLC.

EGK, LLC holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 819,629 shares of Common Stock.

Riva Kay Sheppard holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 1,050,109 shares of Common Stock. Riva Kay Sheppard may be deemed to share beneficial ownership as well as voting and dispositive power with E. Gerald Kay with respect to 169,358 shares of Common Stock.

Christina Kay holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 1,050,109 shares of Common Stock. Christina Kay may be deemed to share beneficial ownership as well as voting and dispositive power with E. Gerald Kay with respect to 169,358 shares of Common Stock.

Robert B. Kay holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 400,000 shares of Common Stock. Robert B. Kay is the manager of EVJ, LLC, and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act) of the 819,629 shares of Common Stock held by EVJ, LLC.

EVJ, LLC holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 819,629 shares of Common Stock.

Carl DeSantis holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 1,540,788 shares of Common Stock. Carl DeSantis is the manager of CDS Group Holdings, LLC, and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act) of the 819,629 shares of Common Stock held by CDS Group Holdings, LLC.

CDS Group Holdings, LLC, holds sole voting and dispositive power, and

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

directly beneficially owns in the aggregate, 819,629 shares of Common Stock.

CUSIP NO. 45811V105

SCHEDULE 13D
Page 13 of 15 Pages

Seymour Flug holds sole voting and dispositive power, and directly beneficially owns in the aggregate, 1,245,033 shares of Common Stock.

(c) Not applicable.

(d) Not applicable.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

The members of the Group individually, and as a whole, do not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

1. Joint Filing Agreement, as required by Rule 13d-1 under the Securities Exchange Act of 1934, as amended.

CUSIP NO. 45811V105

SCHEDULE 13D
Page 14 of 15 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 20, 2006

/s/E. Gerald Kay

E. Gerald Kay, individually

EGK, LLC

Dated: December 20, 2006

By: /s/E. Gerald Kay

Name: E. Gerald Kay
Title: Manager

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

Dated: December 20, 2006 /s/Riva Kay Sheppard

Riva Kay Sheppard, individually

Dated: December 20, 2006 /s/Christina Kay

Christina Kay, individually

Dated: December 20, 2006 /s/Robert B. Kay

Robert B. Kay, individually

EVJ, LLC

Dated: December 20, 2006 By:/s/Robert B. Kay

Name: Robert B. Kay
Title: Manager

Dated: December 20, 2006 /s/Carl DeSantis

Carl DeSantis, individually

CDS Group Holdings, LLC

Dated: December 20, 2006 By:/s/Carl DeSantis

Name: Carl DeSantis
Title: Manager

Dated: December 20, 2006 /s/Seymour Flug

Seymour Flug, individually

CUSIP NO. 45811V105

SCHEDULE 13D
Page 15 of 15 Pages

EXHIBIT INDEX

1. Joint Filing Agreement, as required by Rule 13d- 1 under the Securities Exchange Act of 1934, as amended.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

CUSIP NO. 45811V105

SCHEDULE 13D

JOINT FILING AGREEMENT

The undersigned hereby consent to the joint filing by any of them of a Statement on Schedule 13D and any amendments thereto, whether heretofore or hereafter filed, relating to the securities of Integrated BioPharma, Inc., and hereby affirm that this Schedule 13D is being filed on behalf of each of the undersigned.

Dated: December 20, 2006 /s/E. Gerald Kay

E. Gerald Kay, individually

EGK, LLC

Dated: December 20, 2006 By: /s/E. Gerald Kay

Name: E. Gerald Kay
Title: Manager

Dated: December 20, 2006 /s/Riva Kay Sheppard

Riva Kay Sheppard, individually

Dated: December 20, 2006 /s/Christina Kay

Christina Kay, individually

Dated: December 20, 2006 /s/Robert B. Kay

Robert B. Kay, individually

EVJ, LLC

Dated: December 20, 2006 By:/s/Robert B. Kay

Name: Robert B. Kay
Title: Manager

Dated: December 20, 2006 /s/Carl DeSantis

Carl DeSantis, individually

CDS Group Holdings, LLC

Dated: December 20, 2006 By:/s/Carl DeSantis

Name: Carl DeSantis

Edgar Filing: INTEGRATED BIOPHARMA INC - Form SC 13D

Title: Manager

Dated: December 20, 2006

/s/Seymour Flug

Seymour Flug, individually